Immunology
199.2K views | +31 today
Immunology
Teaching and Learning Immunology. Information you never would have searched for!
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
June 2, 2021 6:48 AM
Scoop.it!

Sick bats stay home alone: fruit bats practice social distancing when faced with an immunological challenge - Moreno - - Annals of the New York Academy of Sciences - Wiley Online Library

Sick bats stay home alone: fruit bats practice social distancing when faced with an immunological challenge - Moreno - - Annals of the New York Academy of Sciences - Wiley Online Library | Immunology | Scoop.it
We demonstrate that in addition to showing the classical mammalian sickness physiological response, sick-like Egyptian fruit bats exhibit voluntary, apparently self-imposed, social distancing. Thi
Scooped by Gilbert C FAURE
June 1, 2021 10:31 AM
Scoop.it!

COVID-19 Immunology 101 for Non-immunologists by Akiko Iwasaki, Ph.D.

In collaboration with BioRender, Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale University School of Medicine, explores COVID-19 Immunology 101 for Non-immunologists.

Acknowledgements:
Dr. Akiko Iwasaki, PhD (Collaborator, narrator, content expert)
Dr. Yanet Valdez Tejeira, PhD (Spanish subtitle contributor)
Mahadi B. Alyami (@RTKase) (Arabic subtitle contributor)
Nick Atanelov (@Nick_atanelov) (Georgian subtitle contributor)
Anonymous (Turkish subtitle contributor)

You can find and customize the figures used in this video by visiting the BioRender template library (http://app.biorender.com/biorender-templates) and search for "tweetorial".

The video is also available in Japanese: https://youtu.be/XAE7U9lCNjg

About BioRender:
BioRender is the easy-to-use science illustration tool that’s quickly becoming a staple in academic institutions and labs around the world! You can access the program for free at https://biorender.com/

BioRender COVID-19 Vaccine & Therapeutics Tracker
https://biorender.com/covid-vaccine-tracker
Scooped by Gilbert C FAURE
May 27, 2021 12:16 PM
Scoop.it!

Had COVID? You’ll probably make antibodies for a lifetime

Had COVID? You’ll probably make antibodies for a lifetime | Immunology | Scoop.it
People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decades, though viral variants could dampen some of the protection they offer.
No comment yet.
Scooped by Gilbert C FAURE
May 25, 2021 11:11 AM
Scoop.it!

LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy | Journal of Experimental Medicine | Rockefeller University Press

LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy | Journal of Experimental Medicine | Rockefeller University Press | Immunology | Scoop.it
LILRB4 strongly suppresses tumor immunity, and LILRB4 blockade alleviates that suppression to provide antitumor efficacy. The authors show that LILRB4 is expres
Gilbert C FAURE's insight:

TAM = tumor associated macrophage

No comment yet.
Suggested by LIGHTING
May 24, 2021 3:13 AM
Scoop.it!

Frontiers | Platelet Activation and the Immune Response to Tuberculosis | Immunology

Frontiers | Platelet Activation and the Immune Response to Tuberculosis | Immunology | Immunology | Scoop.it
In 2019 10 million people developed symptomatic tuberculosis (TB) disease and 1.2 million died. In active TB the inflammatory response causes tissue destruction, which leads to both acute morbidity and mortality. Tissue destruction in TB is driven by host innate immunity and mediated via enzymes, chiefly matrix metalloproteinases (MMPs) which are secreted by leukocytes and stromal cells and degrade the extracellular matrix. Here we review the growing evidence implicating platelets in TB immunopathology. TB patients typically have high platelet counts, which correlate with disease severity, and a hypercoagulable profile. Platelets are present in human TB granulomas and platelet-associated gene transcripts are increased in TB patients versus healthy controls. Platelets most likely drive TB immunopathology through their effect on other immune cells, particularly monocytes, to lead to upregulation of activation markers, increased MMP secretion, and enhanced phagocytosis. Finally, we consider current evidence supporting use of targeted anti-platelet agents in the treatment of TB due to growing interest in developing host-directed therapies to limit tissue damage and improve treatment outcomes. In summary, platelets are implicated in TB disease and contribute to MMP-mediated tissue damage via their cellular interactions with other leukocytes, and are potential targets for novel host-directed therapies.
No comment yet.
Scooped by Gilbert C FAURE
May 19, 2021 1:49 PM
Scoop.it!

The Role of Memory B Cells in Infectious Diseases

The Role of Memory B Cells in Infectious Diseases | Immunology | Scoop.it
The complex role of B cells in response to infectious diseases poses a challenge to understanding infection risks and developing vaccines. Learn about memory B cells and their role in infectious diseases by reading this review that investigates recent advancements in the field.
No comment yet.
Scooped by Gilbert C FAURE
May 19, 2021 11:40 AM
Scoop.it!

Toll-like receptor 2 detects the SARS-CoV-2 envelope protein

Toll-like receptor 2 detects the SARS-CoV-2 envelope protein | Immunology | Scoop.it
Researchers at St Jude Children’s Research Hospital found that toll-like receptor 2 detects the SARS-CoV-2 envelope protein-producing inflammatory cytokines.
No comment yet.
Suggested by LIGHTING
May 15, 2021 12:16 PM
Scoop.it!

CD1a selectively captures endogenous cellular lipids that broadly block T cell response | Journal of Experimental Medicine | Rockefeller University Press

CD1a is expressed on Langerhans cells, where it presents lipid antigens to activate T cells. However, skin cells also produce a natural lipid that binds CD1a an
No comment yet.
Scooped by Gilbert C FAURE
May 15, 2021 12:10 PM
Scoop.it!

Frontiers | Neutrophils: Need for Standardized Nomenclature | Immunology

Frontiers | Neutrophils: Need for Standardized Nomenclature | Immunology | Immunology | Scoop.it
Neutrophils are the most abundant innate immune cell with critical anti-microbial functions. Since the discovery of granulocytes at the end of the nineteenth century, the cells have been given many names including phagocytes, polymorphonuclear neutrophils (PMN), granulocytic myeloid derived suppressor cells (G-MDSC), low density neutrophils (LDN) and tumor associated neutrophils (TANS). This lack of standardized nomenclature for neutrophils suggest that biologically distinct populations of neutrophils exist, particularly in disease, when in fact these may simply be a manifestation of the plasticity of the neutrophil as opposed to unique populations. In this review, we profile the surface markers and granule expression of each stage of granulopoiesis to offer insight into how each stage of maturity may be identified. We also highlight the remarkable surface marker expression profiles between the supposed neutrophil populations.
No comment yet.
Scooped by Gilbert C FAURE
May 13, 2021 12:41 PM
Scoop.it!

Interplay between inflammation and thrombosis in cardiovascular pathology

Interplay between inflammation and thrombosis in cardiovascular pathology | Immunology | Scoop.it
Thrombosis is the most feared complication of cardiovascular diseases and a main cause of death worldwide, making it a major health-care challenge. Platelets and the coagulation cascade are effectively targeted by antithrombotic approaches, which carry an inherent risk of bleeding. Moreover, antithrombotics cannot completely prevent thrombotic events, implicating a therapeutic gap due to a third, not yet adequately addressed mechanism, namely inflammation. In this Review, we discuss how the synergy between inflammation and thrombosis drives thrombotic diseases. We focus on the huge potential of anti-inflammatory strategies to target cardiovascular pathologies. Findings in the past decade have uncovered a sophisticated connection between innate immunity, platelet activation and coagulation, termed immunothrombosis. Immunothrombosis is an important host defence mechanism to limit systemic spreading of pathogens through the bloodstream. However, the aberrant activation of immunothrombosis in cardiovascular diseases causes myocardial infarction, stroke and venous thromboembolism. The clinical relevance of aberrant immunothrombosis, referred to as thromboinflammation, is supported by the increased risk of cardiovascular events in patients with inflammatory diseases but also during infections, including in COVID-19. Clinical trials in the past 4 years have confirmed the anti-ischaemic effects of anti-inflammatory strategies, backing the concept of a prothrombotic function of inflammation. Targeting inflammation to prevent thrombosis leaves haemostasis mainly unaffected, circumventing the risk of bleeding associated with current approaches. Considering the growing number of anti-inflammatory therapies, it is crucial to appreciate their potential in covering therapeutic gaps in cardiovascular diseases. In this Review, Stark and Massberg discuss how the interplay between innate immunity, platelet activation and coagulation, known as immunothrombosis, functions as a host defence mechanism to limit pathogen spreading, yet its aberrant activation, termed thromboinflammation, results in thrombotic complications, highlighting the therapeutic potential of anti-inflammatory strategies in cardiovascular pathologies.




















No comment yet.
Scooped by Gilbert C FAURE
May 2, 2021 4:42 AM
Scoop.it!

UK-CIC Public Webinar: COVID-19 and your immune system | UK-CIC

UK-CIC Public Webinar: COVID-19 and your immune system | UK-CIC | Immunology | Scoop.it
Title: COVID-19 and your immune system Date/Time: Tuesday 4 May 2021 – 18:00 to 19:00 Location: GoToWebinar Register now Description:  The UK Coronavirus Immuno...
Scooped by Gilbert C FAURE
April 25, 2021 7:05 AM
Scoop.it!

Plusieurs formes « d’orages cytokiniques » sont associés à la sévérité et la mortalité dans la Covid-19

Plusieurs formes « d’orages cytokiniques » sont associés à la sévérité et la mortalité dans la Covid-19 | Immunology | Scoop.it
Une étude montre qu’il existe au moins deux profils de réponse cytokinique associée à la Covid-19, ce qui impliquerait donc la nécessité d’une prise en charge hautement personnalisée des patients.
No comment yet.
Scooped by Gilbert C FAURE
April 15, 2021 10:36 AM
Scoop.it!

Alterations in T and B cell function persist in convalescent COVID-19 patients - ScienceDirect

Alterations in T and B cell function persist in convalescent COVID-19 patients - ScienceDirect | Immunology | Scoop.it
Emerging studies indicate that some coronavirus disease 2019 (COVID-19) patients suffer from persistent symptoms, including breathlessness and chronic…
No comment yet.
Scooped by Gilbert C FAURE
June 1, 2021 1:24 PM
Scoop.it!

JCI - Is complement the culprit behind COVID-19 vaccine-related adverse reactions?

Viewpoint Free access | 10.1172/JCI151092 Is complement the culprit behind COVID-19 vaccine-related adverse reactions? Dimitrios C. Mastellos,1 Panagiotis Skendros,2 and John D. Lambris3 Published May 4, 2021 - More info View PDF Rare thrombotic reactions to adenovirus-based COVID-19 vaccines Undeniably, a global and coordinated COVID-19 vaccination effort is a prerequisite for taming the spread of emerging SARS-CoV-2 variants and achieving population-wide immunity that can thwart future viral surges. Ongoing vaccination programs have relied on both mRNA and adenoviral-based formulations eliciting potent humoral responses and showing safety in the majority of the population vaccinated so far. However, rare vaccine-related adverse events were recently reported in individuals who received the adenoviral-encoded ChAdOx1 nCov-19 and Ad26.COV2.S vaccines (1–3). Most of these cases developed acute thrombotic complications (cerebral venous thrombosis or disseminated intravascular coagulation) and severe thrombocytopenia following the first dose of the vaccine, without any prior history of heparin exposure or known risk factors for thrombophilia. This rare syndrome, termed vaccine-induced immune thrombotic thrombocytopenia (VITT), clinically resembles the hallmarks of autoimmune heparin-induced thrombocytopenia (autoimmune HIT) and is linked to the consistent presence of circulating autoantibodies against platelet factor 4 (PF4), which can directly activate platelets in the absence of heparin (2). The prothrombotic action of anti-PF4 antibodies likely involves antibody-mediated platelet activation through IgG-FcγR interactions and similar FcR-mediated engagement of immune effector cells such as monocytes/macrophages and neutrophils (Figure 1). Since VITT is a newly described syndrome, its clinical management mostly relies on its similarities with HIT and non–heparin-dependent autoimmune thrombotic thrombocytopenias. While nonheparin anticoagulants and intravenous immunoglobulin (IVIg) have been proposed as first-line treatments for patients with VITT, these approaches are not fail-safe and entail drawbacks that may curtail their effectiveness (e.g., risk of promiscuous FcR activation, acute anaphylaxis, or even thromboembolic events in the case of intravenous immunoglobulin) (4). Several second-line therapies for HIT have also been suggested, including plasmapheresis, especially when nonheparin anticoagulation is contraindicated because of major bleeding events (5). Thus, more insight into the precise pathophysiology of VITT is needed to enable more personalized medicine approaches. Figure 1 A schematic diagram of the plausible mechanisms by which complement may contribute to the VITT-associated prothrombotic response. Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been described in individuals presenting with high titers of platelet-activating anti–platelet factor 4 (PF4) autoantibodies. These antibodies recognize large multiantigenic complexes comprising PF4 and polyanionic structures similar to heparin, and resemble autoimmune heparin-induced thrombocytopenia (HIT). Complement activation can be triggered in multiple ways in patients presenting with VITT and anti-PF4 antibodies. First, the formation of complexes between PF4 and certain vaccine constituents (e.g., adenoviral capsid proteins or DNA) (23) may serve as a scaffold for C3 activation, similarly to what has been observed with PF4-heparin ultra-large complexes. In addition, complement activation can be triggered by the binding of C1q to the anti-PF4 immune complexes that are deposited on the endothelium, monocyte, or platelet surface via binding to polyanionic structures such as glycosaminoglycans (GAGs). Classical pathway activation leads to C3 cleavage, amplification of complement responses via the alternative pathway, downstream generation of proinflammatory C3a and C5a anaphylatoxins, and the formation of the C5b-9 complex. Complement activation fragments mediate a broad range of thromboinflammatory reactions by interacting with complement receptors on platelets, monocytes, and neutrophils. These interactions can induce or enhance FcR-mediated platelet activation, neutrophil-platelet aggregation, and release of TF-loaded neutrophil extracellular traps (NETs) from activated neutrophils. All these processes are fueled by complement activation and can collectively contribute to a prothrombotic environment that may lead to VITT. Moreover, C3-opsonized immune complexes can enhance FcγR-dependent effector responses on platelets further promoting thrombotic responses. Abbreviations: CP, classical pathway; AP, alternative pathway; TF, tissue factor. A proposed role for complement Complement is a host innate immune sentinel comprising over 50 proteins that can be swiftly activated through any of three initiating pathways (classical, lectin, or alternative) that sense microbial invaders or other inflammatory cues, such as immune complexes. In fact, complement activation has been implicated as a perpetrator of immune complex–driven thromboinflammation in autoimmune pathologies such as the antiphospholipid syndrome, a systemic disorder that increases risk for blood clots (6). Prompted by the striking findings in patients who developed VITT after a single dose of adenoviral-associated vaccine, we posit here that the observed thrombotic complications may partly reflect immune complex–triggered complement activation through the classical pathway. PF4-containing immune complexes can be recognized by C1q, a soluble pattern recognition molecule of the classical pathway that binds to the Fc portion of IgG molecules. Anti-PF4 complex–driven classical pathway activation can lead to C3 activation, alternative pathway–mediated amplification of complement responses, and downstream generation of potent proinflammatory mediators and effectors (C3a, C5a and membrane attack complex) that can potentiate thromboinflammation (7). In fact, the thrombogenic capacity of distinct complement activation fragments has been linked to a broad spectrum of immune-related mechanisms that underpin the immunothrombosis of severe COVID-19 (7, 8). Considering that certain allelic combinations of complement gene polymorphisms within the population confer differential susceptibility to deregulated complement activity, it is tempting to speculate that these vaccinated individuals may represent cases where complement deregulation occurs due to genetic alterations that result in ineffective host regulatory control (9). Deregulated complement responses can perpetuate a vicious cycle of inflammatory tissue damage that renders the vascular endothelium and platelet/monocyte compartment more thrombogenic. In this regard, circulating anti-PF4 immune complexes may well serve as a first hit that ignites complement activation, in a way similar to complement-mediated thrombotic microangiopathies (10). The fact that a fraction of these anti-PF4 autoantibodies may recognize antigenic complexes between PF4 and polyanionic structures (such as GAGs or heparan sulfate) raises the possibility that these immune complexes may skew the binding of endogenous complement regulators to host polyanionic surfaces, thereby altering the capacity of these surfaces to withstand autologous complement attack. C3 activation may play a pivotal pathogenic role in this vaccine-induced immunothrombotic phenotype. C3-opsonized anti-PF4 immune complexes can enhance the phagocytic and inflammatory properties of monocytes and neutrophils through the synergistic engagement of FcγR and complement receptors, thereby increasing the thrombogenic milieu in the vasculature (Figure 1). C3 fragment deposition on the endothelium and on platelets/neutrophils can potentiate thromboinflammatory responses by promoting CR3-dependent platelet-neutrophil interactions that favor platelet adhesion and clotting (11). Also, C3aR signaling on platelets can further drive thrombotic responses (12). Of note, it has been shown that PF4–heparin complexes, a hallmark of HIT pathology, can potently activate C3 in the fluid phase and C3 inhibitors such as Cp40 can abrogate C3 activation triggered by HIT-associated PF4–heparin complexes (13). In line with this, the Cp40-based drug candidate AMY-101 has been shown to effectively decrease both neutrophils and neutrophil extracellular trap (NET) formation, two major drivers of HIT-associated thrombosis, in patients with COVID-19 (7, 14–16). Potential treatment approaches In an analogy to HIT, clinical-stage complement C3 inhibitors may represent a novel therapeutic strategy for ameliorating the thrombotic complications elicited in VITT. On one hand, C3 inhibition may quench anti-PF4 antibody production by reducing antigen uptake or processing in the lymphoid tissue. On the other hand, it can broadly suppress multiple paths of immune complex–driven thromboinflammation in VITT (Figure 1). Moreover, C3 inhibition may offer broader therapeutic control of thromboembolic reactions mediated by pathogenic autoantibodies. In this regard, C3 activation, but not C5, was shown to be indispensable for antiphospholipid antibody-induced tissue factor (TF) activation and thrombosis in antiphospholipid syndrome (17). The recently reported resolution of vaccine-induced thrombotic microangiopathy in two patients following combined treatment with anticoagulants and the C5 inhibitor eculizumab further corroborates our hypothesis that therapeutic complement modulation may offer significant clinical benefits to patients with VITT (18). In this regard, C3 inhibitors may exert a broader therapeutic effect than anti-C5 agents by suppressing both terminal pathway activation and thrombogenic pathways operating upstream of C5 (14, 19). Because this newly described immune syndrome is still poorly defined, it would be of great benefit to patients with VITT if the algorithm for VITT clinical management considered diagnostic monitoring of complement biomarkers as a means of validating the use of specific complement inhibitors. As a cautionary note, we should stress that plasma levels of complement proteins reflect both turnover and synthesis. Therefore, the accurate monitoring of complement activity should rely on markers of ongoing activation combined with corroborative functional assays that gauge the impact of complement activation on the tissue or cellular level. mRNA vaccine reactions In addition to these cases of VITT in individuals receiving adenovirus vectored vaccines, the rollout of COVID-19 mRNA vaccines has brought to the spotlight rare adverse events involving a maladaptive immune reaction to certain vaccine constituents. Rare cases of severe allergic reactions (anaphylaxis) were reported following the first dose of the Pfizer–BioNTech or Moderna SARS-CoV-2 mRNA vaccines (20). Such allergic reactions are likely triggered by the PEG or lipid moieties of these mRNA vaccines. They involve complement and mast cell activation in an IgE-independent manner and closely resemble the complement mediated pseudo-allergy reaction (CARPA) that has been described in the case of liposomal carriers (21). Complement activation in this case may be initiated by IgG or IgM directed against the PEGylated lipids of these vaccine formulations. Concluding remarks Taken together, these paradigms of vaccine-related adverse reactions highlight the potential contribution of complement activation to vaccine-related pathology, raise the importance of incorporating complement diagnostic monitoring in the early clinical management of such patients, and endorse complement inhibitors as potential treatment options. In addition to the complement-activating capacity of anti-PF4 antibodies, we cannot rule out the possibility that complement activation in VITT may also be fueled by preformed (natural IgM) or induced IgG antibodies against adenoviral capsid antigens or direct interaction of pattern recognition molecules with capsid elements (22). The relevance of these plausible mechanisms to VITT pathology warrants further investigation. Footnotes Conflict of interest: JDL is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes. He is the inventor on patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals: US patents 8946145/9371365 (Modified compstatin with peptide backbone and C-terminal modifications), 9630992 (Compstatin analogs with improved pharmacokinetic properties), 9579360 (Methods of treating or preventing periodontitis and diseases associated with periodontitis). JDL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals, i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives such as APL-2/pegcetacoplan/empaveli and APL-9: US patents 6319897 (Peptides which inhibit complement activation), 7989589 (Compstatin analogs with improved activity), 7888323 (Potent compstatin analogs). Copyright: © 2021, American Society for Clinical Investigation. Reference information: J Clin Invest. 2021;131(11):e151092. https://doi.org/10.1172/JCI151092. References Muir K-L, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. [published online April 14, 2021]. N Engl J Med. https://doi.org/10.1056/NEJMc2105869. View this article via: PubMed Google Scholar Scully M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. [published online April 16, 2021]. N Engl J Med. https://doi.org/10.1056/NEJMoa2105385. View this article via: PubMed Google Scholar Schultz NH, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. [published online April 9, 2021]. N Engl J Med. https://doi.org/10.1056/NEJMoa2104882. View this article via: PubMed Google Scholar Kapoor M, et al. Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy. Neurology. 2020;94(6):e635–e638. View this article via: PubMed CrossRef Google Scholar Marchetti M, et al. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med. 2021;10(4):683. View this article via: PubMed CrossRef Google Scholar Chaturvedi S, et al. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol. 2019;10:449. View this article via: PubMed Google Scholar Skendros P, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151–6157. View this article via: JCI PubMed CrossRef Google Scholar Risitano AM, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–344. View this article via: PubMed CrossRef Google Scholar Heurich M, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A. 2011;108(21):8761–8766. View this article via: PubMed CrossRef Google Scholar Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest. 2020;130(5):2152–2163. View this article via: JCI PubMed CrossRef Google Scholar Hamad OA, et al. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thromb Haemost. 2015;114(6):1207–1217. View this article via: PubMed Google Scholar Sauter RJ, et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation. 2018;138(16):1720–1735. View this article via: PubMed CrossRef Google Scholar Khandelwal S, et al. Novel immunoassay for complement activation by PF4/heparin complexes. Thromb Haemost. 2018;118(8):1484–1487. View this article via: PubMed CrossRef Google Scholar Mastellos DC, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. View this article via: PubMed Google Scholar Gollomp K, et al. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight. 2018;3(18):99445. View this article via: JCI Insight PubMed Google Scholar Perdomo J, et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. 2019;10(1):1322. View this article via: PubMed CrossRef Google Scholar Müller-Calleja N, et al. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018;2(9):979–986. View this article via: PubMed CrossRef Google Scholar Tiede A, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccine. [published online April 30, 2021]. Blood. https://doi.org/10.1182/blood.2021011958. View this article via: PubMed Google Scholar Hillmen P, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. View this article via: PubMed CrossRef Google Scholar Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021;384(7):643–649. View this article via: PubMed CrossRef Google Scholar Klimek L, et al. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. [published online March 3, 2021]. Allergy. https://doi.org/10.1111/all.14794. View this article via: PubMed Google Scholar Chéneau C, Kremer EJ. Adenovirus-extracellular protein interactions and their impact on innate immune responses by human mononuclear phagocytes. Viruses. 2020;12(12):1351. View this article via: PubMed CrossRef Google Scholar Greinacher A, et al. Towards understanding ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) [preprint]. https://doi.org/10.21203/rs.3.rs-440461/v1 Posted on Research Square April 20, 2021. Version history Version 1 (May 4, 2021): In-Press Preview Version 2 (June 1, 2021): Electronic publication
No comment yet.
Scooped by Gilbert C FAURE
May 29, 2021 5:01 AM
Scoop.it!

The Immunology Podcast

The Immunology Podcast | Immunology | Scoop.it
Join Drs. Brenda Raud and Jason Goldsmith as they discuss the latest immunology research.
No comment yet.
Scooped by Gilbert C FAURE
May 27, 2021 11:48 AM
Scoop.it!

Select hyperactivating NLRP3 ligands enhance the TH1- and TH17-inducing potential of human type 2 conventional dendritic cells | Science Signaling

Select hyperactivating NLRP3 ligands enhance the TH1- and TH17-inducing potential of human type 2 conventional dendritic cells | Science Signaling | Immunology | Scoop.it
Gilbert C FAURE's insight:

https://medicalxpress.com/news/2021-05-years-discovery-immune-dendritic-cells.html

 

Dendritic cells were discovered in 1868, and at that time were misunderstood and wrongly categorized as members of the nervous system. But immunologists now know there are different types of these cells, even though they all look alike and have roughly the same job as sentinels in the immune system –on patrol 24/7, hunting down infiltrating causes of infection and disease. What separates one group from another, scientists in Germany have just found, is their response to certain signaling molecules and how long they survive in tissues and the blood.

 

Type 1 dendritic cells tend to undergo regulated cell death after inflammasomes activate. But the investigators found that automatic death wasn't inevitable for type 2 DCs, which did not succumb after inflammasome activation. Type 2 DCs not only survived, but continued their role as a bridge between the innate and adaptive immune systems. The researchers suggest that these cells may be prime targets for approaches to treat inflammatory diseases or to boost the effects of vaccines and adjuvants.

"When conventional type 2 dendritic cells were stimulated with ligands that weakly activated the inflammasome, the DCs did not enter [programmed cell death], but instead secreted interleukin-12 family of cytokines [IL-12] and interleukin-1β [IL-1β]. These cytokines induced prominent T helper type 1 cells and T helper 17 responses," the scientists wrote.

Scooped by Gilbert C FAURE
May 24, 2021 1:08 PM
Scoop.it!

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1–7. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent individuals have a significantly lower risk of reinfection8–10. Nonetheless, it has been reported that anti-SARS-CoV-2 serum antibodies experience rapid decay in the first few months after infection, raising concerns that long-lived BMPCs may not be generated and humoral immunity against this virus may be short-lived11–13. Here we demonstrate that in patients who experienced mild infections (n=77), serum anti-SARS-CoV-2 spike (S) antibodies decline rapidly in the first 4 months after infection and then more gradually over the following 7 months, remaining detectable at least 11 months after infection. Anti-S antibody titers correlated with the frequency of S-specific BMPCs obtained from bone marrow aspirates of 18 SARS-CoV-2 convalescent patients 7 to 8 months after infection. S-specific BMPCs were not detected in aspirates from 11 healthy subjects with no history of SARS-CoV-2 infection. We demonstrate that S-binding BMPCs are quiescent, indicating that they are part of a long-lived compartment. Consistently, circulating resting memory B cells directed against the S protein were detected in the convalescent individuals. Overall, we show that SARS-CoV-2 infection induces a robust antigen-specific, long-lived humoral immune response in humans.
No comment yet.
Suggested by LIGHTING
May 20, 2021 3:00 AM
Scoop.it!

How T Cells Recognize SARS-CoV-2

How T Cells Recognize SARS-CoV-2 | Immunology | Scoop.it
Part 1 video in how the immune system recognizes the virus that causes COVID-19
No comment yet.
Scooped by Gilbert C FAURE
May 19, 2021 11:41 AM
Scoop.it!

The 10,000 Immunomes Project: Building a Resource for Human Immunology - ScienceDirect

The 10,000 Immunomes Project: Building a Resource for Human Immunology - ScienceDirect | Immunology | Scoop.it
There is increasing appreciation that the immune system plays critical roles not only in the traditional domains of infection and inflammation but als…...
No comment yet.
Scooped by Gilbert C FAURE
May 19, 2021 7:22 AM
Scoop.it!

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity - ScienceDirect

The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with devastating consequences. While the medical community has gaine…
No comment yet.
Scooped by Gilbert C FAURE
May 15, 2021 12:16 PM
Scoop.it!

Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19

Lowery et al. review the mechanisms by which SARS-CoV-2 activates and antagonizes
the interferon and inflammatory response following infection, how a dysregulated cytokine
and cellular response contributes to immune-mediated pathology in COVID-19, and therapeutic
strategies that target elements of the innate response.
No comment yet.
Scooped by Gilbert C FAURE
May 14, 2021 3:36 PM
Scoop.it!

Six distinct NFκB signaling codons convey discrete information to distinguish stimuli and enable appropriate macrophage responses

Six distinct NFκB signaling codons convey discrete information to distinguish stimuli and enable appropriate macrophage responses | Immunology | Scoop.it
Adelaja and Taylor et al. use a RelA-mVenus reporter mouse to examine, at single-cell
level, the NFκB activation dynamics in primary macrophages responding to different
stimuli. Their findings define six dynamical features—signaling codons—that classify
immune threats and further suggest that signal “confusion” may contribute to autoimmune
pathology.
No comment yet.
Scooped by Gilbert C FAURE
May 11, 2021 3:13 PM
Scoop.it!

Cbl-b deficiency prevents functional but not phenotypic T cell anergy | Journal of Experimental Medicine | Rockefeller University Press

Cbl-b deficiency prevents functional but not phenotypic T cell anergy | Journal of Experimental Medicine | Rockefeller University Press | Immunology | Scoop.it
T cell anergy is an important peripheral tolerance mechanism to prevent autoimmunity. Nguyen et al. find that T cell anergy develops in the periphery, not in th
No comment yet.
Scooped by Gilbert C FAURE
April 29, 2021 6:52 AM
Scoop.it!

Frontiers | The Metabolic Signature of Macrophage Responses | Immunology

Frontiers | The Metabolic Signature of Macrophage Responses | Immunology | Immunology | Scoop.it
Macrophages are a heterogeneous population of immune cells playing several and diverse functions in homeostatic and immune responses. The broad spectrum of macrophage functions depends on both heterogeneity and plasticity of these cells, which are highly specialized in sensing the microenvironment and modify their properties accordingly. Although it is clear that macrophage phenotypes are difficult to categorize and should be seen as plastic and adaptable, they can be simplified into two extremes: a pro-inflammatory (M1) and an anti-inflammatory/pro-resolving (M2) profile. Based on this definition, M1 macrophages are able to start and sustain inflammatory responses, secreting pro-inflammatory cytokines, activating endothelial cells, and inducing the recruitment of other immune cells into the inflamed tissue; on the other hand, M2 macrophages promote the resolution of inflammation, phagocytose apoptotic cells, drive collagen deposition, coordinate tissue integrity, and release anti-inflammatory mediators. Dramatic switches in cell metabolism accompany these phenotypic and functional changes of macrophages. In particular, M1 macrophages rely mainly on glycolysis and present two breaks on the TCA cycle that result in accumulation of itaconate (a microbicide compound) and succinate. Excess of succinate leads to Hypoxia Inducible Factor 1α (HIF1α) stabilization that, in turn, activates the transcription of glycolytic genes, thus sustaining the glycolytic metabolism of M
No comment yet.
Scooped by Gilbert C FAURE
April 25, 2021 3:38 AM
Scoop.it!

T Cell Proliferation - an overview | ScienceDirect Topics

T Cell Proliferation - an overview | ScienceDirect Topics | Immunology | Scoop.it
T Cell Proliferation T cell proliferation leads to formation of millions of T cells expressing specific cell membrane TCRs, capable of binding the most diverse antigens, including self-antigens. From: Epigenetic Principles of Evolution (Second Edition), 2019 Related terms: View all Topics Stem Cell-Based Approach to Immunomodulation Kathryn J. Wood, ... Ou Li, in Regenerative Medicine Applications in Organ Transplantation, 2014 61.3.4 Modulation of T-Cell Responses in Rejection by MSCs T-cell proliferation and activation are prerequisites for allograft rejection [2,85]. A large body of data demonstrate that MSCs can modulate T-cell proliferation, activation, and function both in vitro and in vivo[28,44,86–89]. Moreover, the capacity for MSCs to inhibit Th17 cell differentiation [90,91] or to shift the T-helper cell balance in favor of a more anti-inflammatory phenotype has been demonstrated in vitro [92–96]. The mechanisms utilized by MSCs in mediating these effects vary between in vitro and in vivo models. However, the secretion of soluble factors by MSCs is a common feature (English, 2012). IDO and PGE-2 have been implicated in MSC inhibition of Th17 differentiation [90,91]. In the case of PGE-2, the steps involved in the process require contact-dependent COX-2 induction of PGE-2 and direct inhibition through EP4 [90]. MSCs can also mediate this effect through suppressing the Th17 transcription factor RORγt and upregulating Foxp3 to induce a Treg phenotype producing IL-10 [96]. MSC-derived TGF-β has been shown to play a partial role in shifting the balance of Th1/Th2/Th17 and Treg in an autoimmune disease model [31]. A role for matrix metalloproteinase (MMP)2 and MMP9 secreted by MSCs facilitating cleavage of CD25 expressed on CD4+ T cells thereby inhibiting alloantigen driven proliferation and so preventing islet allograft rejection has also been described [44]. Other evidence suggests that MSC-derived MMPs also cleave CCL2 which subsequently inhibits Th17 activation via a STAT3-dependent pathway [97]. MSCs also have the capacity to expand or induce Treg in the setting of an alloimmune response [43,45,98,99] and in some cases can generate a state of Treg-dependent tolerance [30,45]. Both of these studies elegantly demonstrate the importance of Treg in MSC-induced tolerance using Treg depletion strategies with IDO potentially playing a significant role [30]. In vitro, MSC induction of Treg is thought to involve cell contact, PGE-2, and TGF-β [94]. In vivo, MSC-derived TGF-β was required for the generation of antigen-specific Treg and overall, TGF-β seems to be the major soluble factor involved in MSC promotion of Treg in vivo [29,31,100,101]. T-Cell Activation and Tolerance Erik J. Peterson, Jonathan S. Maltzman, in Clinical Immunology (Fifth Edition), 2019 Coreceptors Transduce Signals That Are Integrated With TCR Signals T-cell proliferation and the initiation of effector function require that the T cell must receive signals in addition to the TCR via other cell surface receptors.18 This requirement for multiple signals allows the T cell to be extremely sensitive to TCR binding while protecting against the inappropriate activation of potentially dangerous effector cells. Because T cells respond to antigens presented on APCs, stimulation under physiological conditions involves the potential engagement of multiple coreceptors on the T cell by cognate ligands on the APCs. Some coreceptors may function to increase the avidity of T cells for interacting APCs. However, many coreceptors exhibit intrinsic signal-transducing capacity. Some signal independently of the TCR; others intersect with TCR-driven signaling machinery. Additionally, coreceptors may function as recruiters of cytoplasmic signaling molecules, including adaptor proteins, as described above. The most intensively studied coreceptors are CD4 and CD8 (Chapter 4). CD4 or CD8 expression on peripheral T cells define subsets that respond to MHC class II- or class I-bound peptide antigens, respectively (Chapter 6). Either CD4 or CD8 can contribute to enhanced TCR signal strength because they each associate with LCK.19 This constitutive interaction, which occurs via specific residues within the CD4 and CD8 cytoplasmic domains, localizes a key effector enzyme to the TCR complex. Cytokines in Hematopoietic Stem Cell Transplantation Kate A. Markey, Geoffrey R. Hill, in Cytokine Effector Functions in Tissues, 2017 IL-6 IL-6 promotes T cell proliferation, the differentiation of cytotoxic T lymphocyte populations, and, when present in combination with TGF-β, promotes Th-17 development.65,66 Preclinical studies of IL-6 in GVHD and GVL confirm its key role as a pathogenic cytokine in GVHD. The absence of IL-6 in the donor T cell pool (using IL-6 deficient donor mice) or systemic blockade of IL-6 with an anti-IL-6R antibody results in decreased aGVHD with no loss of GVL effects in the models used.9,67 Recent data demonstrate that IL-6 is the major cytokine detectable in patient plasma early after BMT and that it appears to play a dominant role in conditioning-related pathology.68 Blockade of IL-6 with tocilizumab (soluble IL-6R) has now progressed through a successful phase I/II clinical trial with low levels of acute GVHD in comparison to historical controls.68 This represents a promising new strategy for GVHD prevention. Macrophages Galen B. Toews, in Asthma and COPD (Second Edition), 2009 Macrophages and Initiation of Antigen-specific T2 Immune Responses in Asthma Resident pulmonary AMs actively suppress T-cell proliferation induced by antigen or polyclonal stimuli [73]. Changes occur within the local inductive milieu of the lung in patients with asthma. AM suppression is reduced after exposure to allergens [106–108]. The tissue microenvironment is a crucial regulator of specific immune response generation (Fig. 11.1). The presence of IgE on APCs likely promotes the uptake and the processing of allergens and their eventual presentation to naïve T-cells. DCs express both FcεR I and FcεR II. These two receptors could function to capture allergen bound to allergen-specific IgE and thus focus the immune response through facilitated antigen presentation [109]. Antigens also deliver signals via quantitative variation in ligand density on APC. Peptide/MHC class II complexes that interact strongly with the TCR favor T1 responses, whereas weak interactions result in the priming of T2 responses. The overall binding affinity can be varied by modifying the peptide, which results in different signals. The mechanisms by which signals delivered via the TCR control differentiation is uncertain; differential TCR aggregation may result in differential intracellular signals that favor distinct cytokine gene expression or certain MHC–TCR interactions may favor differential co-receptor expression [110]. As noted above, co-stimulatory molecules may direct the polarization of T-cells into T1 or T2 cells; B7.2 provides only a moderate signal for T2 cell differentiation; and co-stimulatory signals may be delivered either by the APC that presents the antigen or by the bystander APC. Thus, macrophages may serve as bystander APC and influence DC-induced T-cell proliferation [111]. Soluble cytokines produced by cells of the innate immune response are likely the major regulators of T-cell differentiation (see “Innate Control of Adaptive Immune Responses” section). Immunotherapy in Transplantation Kentaro Akiyama, ... Takuo Kuboki, in Stem Cell Biology and Tissue Engineering in Dental Sciences, 2015 61.2.1.1 Interaction with T-Lymphocytes MSCs are known to inhibit T-cell proliferation by arresting the cell cycle in the G1/G0 phase and down-regulating cyclin D2 expression [6]. As part of the mechanisms involved in this process, MSCs produce a large number of soluble factors that work as anti-inflammatory agents. Di Nicola M et al. reported that human bone marrow MSCs inhibit both CD4+ and CD8+ T-lymphocyte proliferation by secreting transforming growth factor beta 1 (TGFβ1), hepatocyte growth factor (HGF), and prostaglandin E2 (PGE2) in vitro [7]. Another study showed that MSCs inhibit stimulated lymphocyte proliferation and mitogenic response independently of the major histocompatibility complex (MHC) [8]. MSCs also produce indoleamine 2,3-dioxygenase (IDO), which accelerates tryptophan degradation and kynureine synthesis resulting in inhibition of T-lymphocyte proliferation [9]. Nitric oxide (NO) is another immune regulation factor secreted by MSCs [10,11]. NO inhibits proliferation of T-lymphocytes by suppressing phosphorylation of transcription factor, signal transducer, and activator transcription-5 (STAT-5) [12]. Human leucocyte antigen-G5 (HLA-G5) from MSCs is a trigger for inhibition of T-lymphocyte function, followed by up-regulation of T-helper type 2 (Th2) and regulatory T-cell (Tregs) [13,14]. On the other hand, MSCs are able to inhibit T-lymphocyte proliferation by direct cell-to-cell contact [15–17]. Krampera et al. reported that MSCs physically hinder T-lymphocytes from contacting antigen presenting cells in a non-cognate fashion [18]. T-lymphocytes have several subsets. CD8+CTL plays an important role in MHC-dependent allogenic or virus- infected cell depletion. MSCs showed reducing CTL cytotoxicity by inhibiting CTL formation [19]. It has been indicated that the relationship between gamma-delta T-lymphocytes (γδT) and acute graft-vs-host disease (GvHD). MSCs suppress γδT-lymphocyte proliferation without any functional inhibition in vitro (Figure 61.1) [20]. Furthermore, some reports indicated that immunomodulation of MSCs are not only through inhibition of T-lymphocyte proliferation, but also by induction of T-lymphocyte apoptosis. A previous study demonstrated that MSCs secrete IDO, induce 3-Hydroxyanthranilic acid (HAA) synthesis during tryptophan metabolism, and induce cell apoptosis by inhibiting the NFκB pathway in T-lymphocytes [21]. Augello et al. reported that MSCs induce apoptosis of T-lymphocytes by activation of the programmed death 1 pathway [22]. More recently, MSCs have been demonstrated to induce T-lymphocyte apoptosis through the FAS/FAS ligand (FASL) pathway, and consequently lead to immunotolerance (Figure 61.1) [23]. Neuropeptides for Mucosal Immunity David W. Pascual, Kenneth L. Bost, in Mucosal Immunology (Third Edition), 2005 Tachykinins and VIP as costimulation factors for T lymphocytes Early studies showed that SP supports T-cell proliferation (Payan et al., 1983; Stanisz et al., 1986), suggesting that T lymphocytes can express NK1-R. In support of this possibility, recent investigations by several laboratories have demonstrated in vitro and in vivo expression of NK1-R by T lymphocytes. NK1-R mRNA expression by cultured murine (McCormack et al., 1996) and human T cells (Li et al., 2000) or T-cell lines has been reported. In addition, the functionality of NK1-R expression by T lymphocytes has been demonstrated in co-cultures with SP-producing dendritic cells (Lambrecht et al., 1999). It is interesting that NK1-R mRNA expression was observed in intraepithelial and lamina propria T lymphocytes but not in splenic T cells (Qian et al., 2001a). During the host response against respiratory syncytial virus, NK1-R expression was markedly increased in CD4+ T lymphocytes (Tripp et al., 2002). However, the most compelling evidence to date for the importance of NK1-R expression on T lymphocytes comes from studies by Weinstock and colleagues, using a murine model of schistosomiasis. Using NK1-R−/– mice, they observed significant reductions in the size of schistosome-induced granulomas in comparison with disease in wild-type mice (Blum et al., 1999). The limited IFN-γ production by infected NK1-R−/– mice suggested that T cells may be an important target for SP during schistosomiasis. Additional studies clearly demonstrated that the presence of NK1-R on T lymphocytes was largely responsible for schistosome antigen–induced IFN-γ production (Blum et al., 2003). Mechanistic studies demonstrated that schistosome antigen, as well as IL-12, could induce expression of NK1-R during murine schistosomiasis (Blum et al., 2001). Collectively, these studies clearly demonstrate the importance of NK1-R expression and activity during the host response to a parasitic infection. To further address the role of SP contribution to S-IgA responses, NK1-R−/– mice were orally immunized with an attenuated Salmonella construct expressing colonization factor antigen I (CFA/I). This vaccine construct has been shown to elicit a biphasic Th cell response (Pascual et al., 1999) supported by early robust IL-4- and IL-5-producing CD4+ T cells. When such a construct was used to orally immunize NK1-R−/– mice, a significant increase in antigen-specific S-IgA antibody titers was obtained (Trunkle et al., 2003). Surprisingly, no significant differences in IFN-γ production were observed between NK1-R/+/+ and NK1-R−/– mice, but increased production to IL-6 was obtained. This evidence suggests, minimally, that some intracellular infections are resolvable in the absence of NK1-R function, perhaps via increases in S-IgA antibody responses. VIP-containing nerve fibers also extend into the T-cell regions of the Peyer's patches (Ottaway et al., 1987) to affect the CD4+ T cells, whereby stimulation of CD4+ T cells by SP or VIP can affect Ig synthesis. While SP has been shown to exert stimulatory effects upon T cells, VIP has the opposite effect and will inhibit mitogen-induced T-cell proliferation (Stanisz et al., 1986; Ottaway and Greenberg, 1984). This effect apparently occurs through a reduction of IL-2 synthesis (Ottaway, 1987; Metawali et al., 1993) and an inhibition of IL-4 in anti-CD3-stimulated T cells incubated with VIP (Wang et al., 1996). These early studies suggested that VIP exhibited anti-inflammatory properties, but this was not confirmed until recently. As stated earlier, VPAC1 is constitutively expressed, whereas VPAC2 is inducible when T cells are stimulated with anti-CD3 antibody (Delgado et al., 1996). Upon stimulation, VPAC1 levels decrease, while VPAC2 levels are induced. This evidence suggests that VIP action on CD4+ T cells is via the effect of VPAC2 acting specifically upon Th2 cells. To begin to address the regulation of VPAC1 and VPAC2, a mouse deficient in VPAC2 was derived and exhibited enhanced delayed-type hypersensitivity (DTH) responses supported by increased IFN-γ production (Goetzl et al., 2001). To exacerbate Th2 cell function, a transgenic mouse was derived in which CD4+ T cells express the human VPAC2 (Voice et al., 2001). These mice showed increased serum IgE and IgG1 but not IgA antibodies. This Th2 cell bias was evidenced as enhanced susceptibility to TNP-induced cutaneous anaphylaxis and depressed DTH responses. Studies have yet to determine whether VPAC1 and VPAC2 are regulated in a similar fashion by Peyer's patch Th cells, in a manner analogous to that seen with splenic Th cells. Bone Marrow DANIEL A. ARBER, in Modern Surgical Pathology (Second Edition), 2009 T-CELL PROLYMPHOCYTIC LEUKEMIA T-PLL is a clonal T-cell proliferation that occurs most commonly in elderly patients and has a slight male predominance.328,372,373 The disease also occurs frequently in younger patients with ataxia telangiectasia.374 Patients have a markedly elevated white blood cell count as well as organomegaly and lymphadenopathy. Nodular or maculopapular skin lesions are also common. The peripheral blood white blood cell count is usually greater than 100 × 109/L with a predominance of medium-sized cells with abundant basophilic cytoplasm and a single prominent nucleolus (Fig. 43-27). These cells are similar to B-cell prolymphocytes but may have a more convoluted nucleus than in B-PLL. Normocytic anemia and thrombocytopenia are common. The bone marrow may not be involved to the degree that would be expected by the marked elevation in peripheral blood prolymphocytes. The pattern of involvement may be interstitial, diffuse, or mixed and reticulin fibrosis is frequently present (Fig. 43-28).353 In general, T-PLL is an aggressive disease with short survival. However, a subpopulation of patients with T-PLL, including many with ataxia telangiectasia, have an initial, indolent disease course that eventually transforms to the more typical aggressive disease.375 Immunophenotyping is necessary to distinguish T-PLL from B-PLL and is often helpful in excluding acute leukemia. T cell-associated antigens CD2, CD3, CD5, and CD7 are expressed by T-PLL and surface CD3 is present. Most cases are CD4+, but a subset of cases expresses CD8 or both CD4 and CD8. The absence of both CD20 and immunoglobulin light-chain expression excludes B-PLL. The lack of TdT and CD1a expression and the presence of surface CD3 exclude most cases of T-cell ALL. T-cell receptor gene rearrangements are uniformly detectable in T-PLL. Cytogenetic abnormalities in T-PLL include inv(14)(q11q32) and t(14;14)(q11;q32), involving the TCL1 gene in the region of the T-cell receptor α/β locus, iso(8q), trisomy 8, 12p13 deletions, and t(X;14)(q28;q11).375,376 Abnormalities of chromosome region 11q22-23, involving the ATM tumor suppressor gene that is consistently mutated in ataxia telangiectasia are present in some patients with T-PLL even in the absence of ataxia telangiectasia.377 Some T-cell chronic lymphoproliferative disorders have cells with morphologic features similar to those of B-CLL without the prominent nucleolus typical of usual-type PLL.378,379 Cases of this type are considered small cell variants of T-PLL, and the term T-cell CLL should no longer be used. Although the median age and white blood cell count are lower in these patients than in usual-type T-PLL, these cases have immunophenotypic and cytogenetic features similar to those of T-PLL and a similarly aggressive clinical course. Development of T Cell Immunity Jeong M. Kim, in Progress in Molecular Biology and Translational Science, 2010 E Granzyme Dependent Cytotoxicity Treg cell mediated inhibition of in vitro effector T cell proliferation was demonstrated to require cell-to-cell contact. Although the molecular basis for contact-mediated suppression is largely unknown, recent reports have revealed that Tregs also require cellular contact for target cell killing via the granule exocytosis pathway.150,151 Granule-mediated cytoxicity is dependent on granzymes, granule resident proteases, which initiate a cascade of apoptosis-promoting cleavage events. As in effector T cells, granzyme expression is induced in Tregs in response to T cell receptor signaling. While granzyme A is primarily expressed by activated human Tregs,151 granzyme B is the predominant granzyme induced in murine Tregs.150 Granzyme A and B differ in substrate specificity and the kinetics of cell death induction, but activated murine and human Tregs comparably induce effector T cell death at 1:1 ratio of regulatory to effector T cells. In vitro cytotoxicity was dependent on granzyme function, as suppression of effector T cell proliferation was severely compromised in cultures containing granzyme B deficient Tregs.150 Cytolytic granules also contain perforin, which is essential for target cell lysis in CD8+ CTLs and NK cells. The deposited perforin polymerizes on the target cell plasma membrane in a calcium dependent manner and generates holes that were hypothesized to serve as granzyme conduits into the target cell. However, accurate measurements of pores formed by perforin suggest that the diameter of polyperforin channels do not accommodate granzyme passage.152 Although the exact function of perforin remains unknown, phenotypic similarities in mice deficient in either perforin or granzyme B provide evidence that perforin plays a nonredundant role in targeted cytolysis by lymphocytes. In support of this idea, inhibiting perforin by either EDTA or concanamycin A treatment abrogates target cell killing by human Tregs. In contrast to these findings, perforin deficient murine Tregs were equally suppressive as its wild-type counterparts in vitro, suggesting that perforin is not essential for granzyme B dependent target cell lysis in murine Treg cells. These discrepant results may reflect the usage of different granzymes for target cell killing in mouse versus human Tregs. In this regard, granzyme A may be more dependent on perforin for killing that granzyme B. Alternatively, calicium chelators or concanamycin A may not be specific for perforin inhibition, affecting target cell cytolysis independent of perforin function. Human Tregs, additionally, have been demonstrated to kill monocytes, DCs, and activated CD8+ T cells151 (Fig. 3B). Murine Tregs are also capable of killing B cells in vitro.114 Assay for Antigen-Specific T-Cell Proliferation in Mice Şefik Ş. Alkan, in Immunological Methods, 1979 Publisher Summary This chapter discusses the assay for antigen-specific T-cell proliferation in mice. While lymphocyte proliferative responses to allogeneic cells or to mitogens in the mouse can be readily measured, the reliable assay of antigen-induced T-lymphocyte proliferation in culture has proved to be substantially more difficult to establish. The uncontrolled nature of proliferation and the contribution of B-cell responses have made these methods of questionable value as a T-cell assay. The novel features of the method are the use of only draining lymph node cells of primed mice instead of spleen cells and the use of horse serum in the culture medium instead of fetal calf serum. Only draining lymph node cells rich for antigen-reactive cells are used. Animals are sensitized by injecting antigen into the tail or footpads, the draining lymph nodes are removed, the cells are cultured in microculture plates in the presence or absence of antigens (and/or mitogens), and proliferation is measured by [3H] thymidine uptake. This technique can be used for several antigens, such as monovalent antigens and protein antigens. The Digestive Involvement in Systemic Autoimmune Diseases A.J. Czaja, in Handbook of Systemic Autoimmune Diseases, 2017 4.4 Regulatory T Cells Regulatory CD4+CD25+ T cells modulate CD8 T cell proliferation by exerting a direct suppressive effect on the production of IFN-γ while increasing secretion of IL-4, IL-10, and TGF-β [143–146]. They can also induce the apoptosis of inflammatory and immune cells [147], inhibit hepatic stellate cells [148], impair the secretion of IL-17 [149], and limit the proliferation of Th17 lymphocytes [149]. These cells have been decreased in number and function in the peripheral blood of patients with autoimmune hepatitis [144,150,151], and they have been less evident in the portal tracts of liver specimens (Table 2.3) [151]. A signaling defect that influences the function of the regulatory T cells may also contribute to regulatory failure [5]. Galectin 9 is a beta galactosidase–binding protein expressed on regulatory T cells, and its ligation with the mucin domain-3 receptor (TIM-3) on Th1 cells and dendritic cells induces the apoptosis of Th1 lymphocytes and dendritic cells [152,153]. In autoimmune hepatitis, the expression of galectin 9 on regulatory T cells and TIM-3 on Th1 cells is reduced, and these deficiencies may limit the ability of the regulatory T cells to restore immune tolerance [153]. Deficiencies in the function of regulatory T cells have also been described in the siblings and children of patients with PBC, and the suppressor activity of this subset may be modulated by genetic factors [146]. Regulatory T cells can be defined more rigidly by the phenotype CD4+CD25+CD127+(low)Foxp3+, and cells with this phenotype have had normal function in patients with autoimmune hepatitis. Furthermore, increased numbers of these cells have been described in the peripheral circulation and liver tissue of patients with autoimmune hepatitis [154]. These findings have challenged the hypothesis that perturbations in the regulatory T cell population are critical for the development of autoimmune hepatitis. The discrepant findings between studies may relate to differences in the phenotypic definition of the regulatory T cells, methods for the detection and evaluation of these cells, and the severity and treatment of the liver disease in the study population [155]. The abnormalities associated with regulatory T cells may be transient and improved by medications (corticosteroids, mycophenolate mofetil, or rapamycin) and the resolution of inflammatory activity [5,144]. Relative imbalances between the number and functions of the regulatory T cells and effectors cells may be the critical factor affecting the autoreactive response rather than the absolute number and function of an individual cell population.
Michael Craver 's curator insight, June 17, 2021 8:19 PM

https://vaporwavepsychedelic.com
https://vaporwavepsychedelic.com/product/buy-2-c-b-drug/
https://vaporwavepsychedelic.com/product/buy-4-aco-dmt/
https://vaporwavepsychedelic.com/product/buy-5-meo-dmt/
https://vaporwavepsychedelic.com/product/ayahuasca-tea/
https://vaporwavepsychedelic.com/product/buy-changa/
https://vaporwavepsychedelic.com/product/dmt-vape-pen/
https://vaporwavepsychedelic.com/product/golden-teacher-mushrooms/
https://vaporwavepsychedelic.com/product/ibogaine-for-sale/
https://vaporwavepsychedelic.com/product/ketamine-drug/
https://vaporwavepsychedelic.com/product/buy-khat-plant-online/
https://vaporwavepsychedelic.com/product/buy-kratom-powder-online/
https://vaporwavepsychedelic.com/product/liberty-caps-mushrooms/
https://vaporwavepsychedelic.com/product/liquid-lsd/
https://vaporwavepsychedelic.com/product/buy-lsd-gel-tabs/
https://vaporwavepsychedelic.com/product/buy-lsd-gummies/
https://vaporwavepsychedelic.com/product/buy-lsd-tabs/
https://vaporwavepsychedelic.com/product/mdma-drug/
https://vaporwavepsychedelic.com/product/peyote-cactus/
https://vaporwavepsychedelic.com/product/buy-pcp-drug/
https://vaporwavepsychedelic.com/product/penis-envy-mushrooms/
https://vaporwavepsychedelic.com/product/buy-dmt/

keshavdamani3@gmail.com's curator insight, August 19, 2021 1:08 AM
progressive ataxia and multisystem involvement, which requires early diagnosis and multidisciplinary management..Read more from https://www.pediatriconcall.com/pediatric-journal/view/fulltext-articles/1315/J/0/0/710/0